Literature DB >> 11303954

Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats.

T Uchiyama1, A Kotani, H Tatsumi, T Kishida, A Okamoto, N Okada, M Murakami, T Fujita, Y Fujiwara, Y Kiso, S Muranishi, A Yamamoto.   

Abstract

PURPOSE: The objective of this study is to examine the intestinal permeability of novel lipophilic derivatives of DADLE (Tyr-D-Ala-Gly-Phe-D-Leu), an enkephalin analogue, using isolated rat intestinal membranes.
METHODS: The novel lipophilic derivatives of DADLE were synthesized by chemical modification with various fatty acids at the C terminus. The pharmacological activities of these DADLE derivatives were assessed by a hot plate test. The intestinal permeability of these derivatives was estimated by the in vitro Ussing chamber method.
RESULTS: We obtained four different DADLE derivatives including acetyl-DADLE (DADLE-C2), butyryl-DADLE (DADLE-C4), caproyl-DADLE (DADLE-C6), and caprylyl-DADLE (DADLE-C8). All the derivatives of DADLE had at least 75% of the activity of native DADLE, suggesting that chemical modification of DADLE at the C terminus did not markedly affect its pharmacological activity. These DADLE derivatives were more stable than native DADLE in jejunal and colonic homogenates. A "bell-shaped" profile was observed between the apparent permeability coefficients (Papp) of DADLE derivatives and lipophilicity. In particular, DADLE-C4 had the greatest permeability characteristics across the intestinal membrane of the acyl derivatives studied in this experiment. The permeability of DADLE-C4 across the jejunal membrane was further improved in the presence of puromycin, amastatin, and sodium glycocholate (NaGC), all at a concentration of 0.5 mM.
CONCLUSIONS: We suggest that the combination of chemical modification with butyric acid and the application of a protease inhibitor are effective for improving the absorption of DADLE across the intestinal membrane.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11303954     DOI: 10.1023/a:1007644706286

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Improvement of intestinal absorption of thyrotropin-releasing hormone by chemical modification with lauric acid.

Authors:  K Yamada; M Murakami; A Yamamoto; K Takada; S Muranishi
Journal:  J Pharm Pharmacol       Date:  1992-09       Impact factor: 3.765

2.  A classification of opiate receptors that mediate antinociception in animals.

Authors:  M B Tyers
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

3.  Improvement of intestinal absorption of leucine enkephalin by sugar coupling and peptidase inhibitors.

Authors:  T Mizuma; K Ohta; A Koyanagi; S Awazu
Journal:  J Pharm Sci       Date:  1996-08       Impact factor: 3.534

4.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

5.  Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid.

Authors:  K Tanaka; T Fujita; Y Yamamoto; M Murakami; A Yamamoto; S Muranishi
Journal:  Biochim Biophys Acta       Date:  1996-08-14

6.  Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers.

Authors:  V B Lang; P Langguth; C Ottiger; H Wunderli-Allenspach; D Rognan; B Rothen-Rutishauser; J C Perriard; S Lang; J Biber; H P Merkle
Journal:  J Pharm Sci       Date:  1997-07       Impact factor: 3.534

7.  Effects of various protease inhibitors on the stability and permeability of [D-Ala2,D-Leu5]enkephalin in the rat intestine: comparison with leucine enkephalin.

Authors:  T Uchiyama; A Kotani; T Kishida; H Tatsumi; A Okamoto; T Fujita; M Murakami; S Muranishi; A Yamamoto
Journal:  J Pharm Sci       Date:  1998-04       Impact factor: 3.534

8.  Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes.

Authors:  A Yamamoto; E Hayakawa; V H Lee
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

9.  Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids.

Authors:  K Setoh; M Murakami; N Araki; T Fujita; A Yamamoto; S Muranishi
Journal:  J Pharm Pharmacol       Date:  1995-10       Impact factor: 3.765

10.  Studies on the transport of enkephalin-like oligopeptides in rat intestinal mucosa.

Authors:  G A Kerchner; L E Geary
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

View more
  5 in total

Review 1.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 2.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

3.  Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity.

Authors:  Weiqiang Cheng; Seetharama Satyanarayanajois; Lee-Yong Lim
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

4.  Acylation of Glucagon-like peptide-2: interaction with lipid membranes and in vitro intestinal permeability.

Authors:  Sofie Trier; Lars Linderoth; Simon Bjerregaard; Thomas Lars Andresen; Ulrik Lytt Rahbek
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

5.  An Effective and Safe Enkephalin Analog for Antinociception.

Authors:  K K DurgaRao Viswanadham; Roland Böttger; Lukas Hohenwarter; Anne Nguyen; Elham Rouhollahi; Alexander Smith; Yi-Hsuan Tsai; Yuan-Yu Chang; Christopher Llynard Ortiz; Lee-Wei Yang; Liliana Jimenez; Siyuan Li; Chan Hur; Shyh-Dar Li
Journal:  Pharmaceutics       Date:  2021-06-22       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.